Polymorphic crystalline forms of Ibandronate sodium were found, referred to hereinafter as polymorphic Form α, Form β, Form ε, Form δ, Form γ and Form ζ. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms, to pharmaceutical compositions comprising them, as well as their use.Linvention concerne des formes cristallines polymorphes dibandronate sodium, nommées dans le présent document forme polymorphe α, forme β, forme ε, forme δ, forme γ et forme ζ. La présente invention concerne également des procédés de préparation de ces formes cristallines, des compositions pharmaceutiques qui les comprennent, ainsi que leur utilisation.
